Novo Nordisk
2013-03-18T11:32:31Z
2013-03-18T11:32:31Z
People with type 2 diabetes achieve 6% weight loss with liraglutide 3 mg in phase 3a obesity trial
Bagsværd, Denmark, 18 March 2013 - Novo Nordisk today announced the headline results from a 56-week, double-blind phase 3a clinical trial investigating the potential of liraglutide to induce and maintain weight loss in overweight or obese people with type 2 diabetes. This is the second phase 3a trial to be completed as part of SCALE(TM), the clinical development programme for liraglutide 3 mg as an obesity treatment.
Further information
| Media: | ||
| Katrine Sperling | +45 3079 6718 | krsp@novonordisk.com |
| Ken Inchausti | +1 609 786 8316 | kiau@novonordisk.com |
| Ambre Morley | +1 609 987 5898 | abmo@novonordisk.com |
| Investors: | ||
| Kasper Roseeuw Poulsen | +45 4442 4303 | krop@novonordisk.com |
| Frank Daniel Mersebach | +45 4442 0604 | fdni@novonordisk.com |
| Lars Borup Jacobsen | +45 3075 3479 | lbpj@novonordisk.com |
| Jannick Lindegaard (US) | +1 609 786 4575 | jlis@novonordisk.com |
Company announcement No 19 / 2013